Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...

Kevin Smith, a resident of Clifton Park, is experiencing the benefits of a recently approved Alzheimer's drug, Leqembi, as he ...

HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.